LONDON (Reuters) - Three of Europe’s top drugmakers have backed a new public-private scheme to use stem cells for safety testing of experimental medicines, signaling “big pharma’s” growing interest in the controversial field.
LONDON (Reuters) - Three of Europe’s top drugmakers have backed a new public-private scheme to use stem cells for safety testing of experimental medicines, signaling “big pharma’s” growing interest in the controversial field.
